General Information of Drug (ID: DMLHF3E)

Drug Name
Conantokins G Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMLHF3E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [2]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [3]
CP-101,606 DMIU19E Parkinson disease 8A00.0 Phase 2 [4]
CERC-301 DMSABRI Major depressive disorder 6A70.3 Phase 2 [5]
RGH-896 DMCHZAN Peripheral neuropathy 8C0Z Phase 2 [6]
MIJ821 DMN45RI Major depressive disorder 6A70.3 Phase 2 [7]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [8]
Neu-2000 DMNJTLC Cardiac arrest MC82 Phase 1 [9]
EVT100 DMAKWQD Major depressive disorder 6A70.3 Phase 1 [10]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor ionotropic NMDA 2B (NMDAR2B) TTN9D8E NMDE2_HUMAN Antagonist [1]

References

1 Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16.
2 NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
3 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
4 NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
5 Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
6 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
7 Clinical pipeline report, company report or official report of Cadent Therapeutics.
8 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
9 Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.